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SUPPLEMENTAL APPENDIX 
 
Additional details on the El Cuete cohort  
Epidemiological data from the El Cuete IV prospective cohort study were used to inform our 
findings on needle and syringe program (NSP) utilization.  Study details have been described 
previously.1  Briefly, eligibility criteria at baseline included injecting drugs in the past month, 
being at least 18 years old, and not planning to move away from Tijuana over the next 30 months.  
Participants were recruited by street outreach from March 2011 – May 2013 (N=734), 
contributing 4,301 study visits in this analysis.  Participants were followed biannually, however 
participants were not required to have injected drugs in the previous six months at their follow-up 
visits.  All participants provided informed consent.  The study protocol was approved by the 
University of California San Diego Human Research Protections Program and El Colegio de la 
Frontera Norte (Tijuana).  
 
Measures 
Our outcome of interest was accessing a NSP (either participants themselves or from someone 
else who obtained syringes from a NSP) in the past six months.  The independent variable of 
interest was the calendar period, which we classified according to its respective GF period 
(during and post-GF).  The surveys from all visits were sorted in ascending order based on the 
date of the interview.  Next, they were grouped into three-month periods with each period 
corresponding to a different GF period (during and post-GF).  We note that while the actual 
follow-up visits were spaced approximately 6 months apart and the surveys inquired about NSP 
utilization in the past 6 months, the calendar periods were grouped into three-month periods to 
allow us to capture and estimate any seasonal variation that might have occurred within each GF 
period.  For simplicity, in terms of when El Cuete participants may have begun noticing the 
impact of the GF, we classified the GF period as beginning in March 2012 and ending before 
June 2014 given that participants were asked about behaviors in the past 6 months.  While the 
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dates did not align exactly with the reported GF start and end times, we assumed that it most 
likely took the GF sponsored activities a few months to “ramp up” and “wind down”.  For 
example, prevention programs did not begin to be implemented in Tijuana until the third trimester 
of 2011.2  In total, the data were divided into 17 evenly spaced three-month time periods, 9 of 
which occurred during the GF period and 8 in the post-GF period.  On average, there were 
approximately 200-300 visits per three-month period.  
 
Statistical analyses 
We conducted segmented regression, a method used in the evaluation of intervention effects for 
interrupted time series data.3  Logistic regression with fixed and random effects was used to 
estimate the mean log (odds of accessing a NSP) during the previous six months for each of the 
17 three-month periods.  Next, the mean log odds for each period estimated by the logistic 
regression model were used as the outcome variable in a segmented regression analysis, to predict 
the trend of accessing a NSP within each GF period as well as the level change from the GF 
period to the post-GF).  Given the lack of independent error terms (as the errors of time series 
data are usually autocorrelated), a linear regression model was fitted to account for the 
autoregressive error.  We tested for autocorrelation using the Breusch-Godfrey test and included 
first-order and second-order autoregressive terms to adjust for the effect of the positive 
autocorrelation.  
 
RESULTS 
The mean predicted probabilities of accessing a NSP over the 17 three-month periods are shown 
in Figure S1.  Overall, there was a significant increasing trend in the probability of accessing the 
NSP during the GF period, which peaked in September 2013 (51%, 95% CI: 42% - 59%).  During 
the GF period, the mean log odds of accessing a NSP in the increased by a factor of 0.17 (p-value 
< 0.001).  The level change (the immediate change that occurred between the end of the last 
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three-months of the GF period and the end of the first three months of the post-GF period) from 
the GF period to the post-GF period was associated with a 0.73 reduction in the mean log odds of 
accessing a NSP in the past 6 months (p=0.02).  During the post-GF period, the mean log odds of 
accessing a NSP decreased by a factor of 0.22 (p=0.002).   
 
These trends were roughly consistent with national estimates of syringes acquired with GF 
support.  In 2011, 534,573 syringes were distributed (92,070 financed by the GF [note: some sites 
may have been receiving funds prior to the NSP in Tijuana]), increasing to 1,904,961 syringes 
distributed (1,199,520 from the GF) in 2012.  In 2013, 3,235,372 syringes were distributed with 
78% provided by the GF (2,508,840).  By 2014, the number of syringes distributed nationally 
declined to 643,320.4  
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Figure S1: Mean predicted probability of accessing a syringe exchange program in past six 
months among PWID in Tijuana.  Error bars represent 95% confidence intervals.  
Shaded box represents the calendar period when the Global Fund operated in Mexico.  
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Figure S2: Number of syringes distributed in Mexico 2011 – 20144 
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